KLOW
Preclinical ResearchKLOW blend (KPV + GHK-Cu + BPC-157 + TB-500)
A four-peptide blend that adds KPV to the GLOW combination, researched for gut, skin and inflammatory conditions.
Dose
Set by the vial label ratio rather than a single number. A 10 mg KPV / 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 vial is typically dosed to deliver roughly 250-500 mcg each of KPV, BPC-157 and TB-500, which brings 1.25-2.5 mg GHK-Cu along with it.
Route
Subcutaneous injection, Oral (KPV component in some protocols), Topical
Cycle
4-8 weeks
Storage
Store the sealed lyophilized vial at 2-8°C protected from light. Long-term storage at -20°C preserves potency for 12-24 months. Keep the vial boxed — the copper component is light-sensitive.
What is KLOW?
KLOW is the GLOW blend with a fourth peptide added: KPV, the C-terminal tripeptide of alpha-MSH. KPV is the only anti-inflammatory member of the group — it suppresses NF-kB and pro-inflammatory cytokine signaling in cell and rodent models of colitis and dermatitis, which is why the blend is marketed for gut and skin conditions rather than pure tissue repair. The other three components are unchanged: GHK-Cu for collagen and skin remodeling, BPC-157 for rodent-model soft tissue and gut healing, and TB-500 for cell migration and angiogenesis. Common research-market vials run 10 mg KPV / 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500, but ratios vary by vendor. As with GLOW, no study has ever examined the blend as a unit; the entire rationale is assembled from four separate literatures, and KPV's own human evidence is thin — mostly in-vitro and animal colitis models, with oral and topical routes better represented than injection.
Key Benefits
- Researched for intestinal inflammation
- Researched for inflammatory skin conditions
- Researched for soft-tissue and wound repair
- Researched for collagen synthesis
- Combines an anti-inflammatory peptide with three repair-oriented ones
Mechanism of Action
- KPV: inhibition of NF-kB nuclear translocation and downstream pro-inflammatory cytokine production
- KPV: uptake through the PepT1 transporter expressed on inflamed intestinal epithelium
- GHK-Cu: copper delivery driving collagen, elastin and glycosaminoglycan synthesis
- BPC-157: growth factor receptor upregulation in injured tissue (rodent data)
- TB-500: actin sequestration supporting cell migration and angiogenesis (animal data)
Best For
- Gut inflammation research
- Inflammatory skin research
- Soft-tissue recovery research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
No single value — blend. KPV 361.4 g/mol · GHK-Cu 340.7 g/mol (copper complex) · BPC-157 1419.5 g/mol · TB-500 ~4963 g/mol
Length
3 aa (KPV) · 3 aa (GHK-Cu) · 15 aa (BPC-157) · synthetic thymosin beta-4 fragment (TB-500)
Type
Multi-compound blend (four-part vial)
Amino acid sequence
KPV: Lys-Pro-Val | GHK-Cu: Gly-His-Lys + Cu(II) | BPC-157: Gly-Glu-Pro-Pro-Pro-Ala-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Lys-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH
KLOW is a four-peptide blend, so it has no single molecular weight, sequence or amino acid count — each component keeps its own. What a given unit of volume actually delivers depends entirely on the mg ratio printed on your vial label, which differs between vendors. Always calculate from the one component you are targeting rather than the combined vial weight.
Pharmacokinetics
Time to peak
Per component: KPV and GHK-Cu peak within minutes of subcutaneous injection; BPC-157 around 1-2 hours; TB-500 distributes over hours.
Half-life
48 h
Time to clear
Staggered. KPV and GHK-Cu are cleared within minutes to about an hour. BPC-157 clears systemically within roughly 1-2 days. TB-500 is the longest-acting component and can persist for several days, which is why the listed half-life reflects TB-500 — the other three are long gone before it clears.
No pharmacokinetic study has ever been run on the KLOW blend. Every figure here is inferred from the four components studied separately, mostly in animal models, and none of it accounts for how a combined injection behaves.
Research Indications
Rodent colitis models
KPV reduces NF-kB signaling and pro-inflammatory cytokine output in DSS and TNBS colitis models, with reduced mucosal damage scores.
Route mismatch
Most of the supportive KPV work is oral or topical, delivered locally to inflamed tissue. KLOW is sold as an injection, which is the least evidence-aligned route for this indication.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Gut-focused research | 250-500 mcg KPV equivalent | Once daily | Subcutaneous — though oral KPV matches the underlying literature far better |
| Inflammatory skin research | 250-500 mcg KPV equivalent, delivering 1.25-2.5 mg GHK-Cu at a typical ratio | Once daily, 4-8 weeks | Subcutaneous, rotating sites |
| Soft-tissue recovery research | 250-500 mcg BPC-157 equivalent | Once daily, or 2-3x weekly on TB-500-weighted schedules | Subcutaneous, abdominal |
| Localized / site-directed research | 250 mcg BPC-157 equivalent | Once daily for 2-4 weeks | Subcutaneous near the target tissue |
| Maintenance after an initial block | Half the loading amount | 2-3x weekly | Subcutaneous, after a 4-week break |
No pharmacokinetic requirement for a particular time of day. Gut-oriented protocols commonly use morning dosing on an empty stomach; consistency matters more than the clock.
Peptide Interactions
How to Reconstitute
- 1Bring the sealed vial to room temperature first.
- 2Swab both the blend vial and the bacteriostatic water stopper with fresh alcohol.
- 3Draw your chosen volume of bacteriostatic water — 2 mL or 3 mL for a typical 80 mg blend vial.
- 4Run the water down the inside wall of the vial rather than directly onto the powder.
- 5Swirl gently until fully dissolved; never shake.
- 6Label the vial with the date and the mg of each of the four components, then refrigerate.
Calculate from the mg of the single component you are actually targeting — usually KPV or BPC-157 — not the combined vial weight. Everything else in the vial rides along at whatever ratio the vendor chose.
What to Expect
- A blue-green solution after reconstitution — that is the copper component and is expected.
- Stinging or flushing at the injection site, most often from GHK-Cu. Rotate sites.
- No way to attribute any change to a specific component — four variables, one syringe.
- Gut-oriented effects, if any, appearing over 1-4 weeks in the animal literature rather than immediately.
- Skin quality changes described over 4-12 weeks, and only in topical GHK-Cu studies.
- Vendor-to-vendor variation in what a given volume delivers, because ratios differ.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Injection site redness, stinging or flushing | Common | Mild |
| Injection site irritation from the copper component | Common | Mild |
| Transient nausea or loose stools | Uncommon | Mild |
| Headache or fatigue | Uncommon | Mild |
| Unknown long-term effects from combined chronic exposure | Unknown | Unknown |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.